The U.S. drug regulator asked Pfizer, Eli Lilly and AbbVie to include information about the risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors.
The National Institutes of Health (NIH) is testing a booster shot of Covid-19 vaccines in people with autoimmune diseases who have not responded well to the primary vaccine course.
After the historic approval of the company’s first-ever drug in January 2021, Aurinia Pharmaceuticals announced the acquisition of two pipeline assets that align with the Canadian biotech’s focus on autoimmune and kidney-related disease.
Global pharmaceutical giant Pfizer Inc. announced that the company’s trial on a potential treatment for alopecia areata achieved the study’s primary efficacy endpoint.
AstraZeneca’s Saphnelo (anifrolumab-fnia) was approved in the United States for the treatment of adult patients with moderate to severe systemic lupus erythematosus who are receiving standard therapy.
Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.
Pfizer Inc.’s oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized Covid-19 patients with pneumonia in Brazil, meeting the study’s main goal.
The U.S. Food and Drug Administration approved Novartis’ blockbuster drug Cosentyx (secukinumab) for pediatric patients aged 6 years and older with moderate-to-severe plaque psoriasis. The new approval for Cosentyx marks the first for a pediatric patient population in the United States.
Alloy Therapeutics and Pyxis Oncology announced the formation of their joint venture, Kyma Therapeutics, which will develop immune-modulating antibodies in an attempt to tackle cancer and autoimmune diseases.
During the Digestive Disease Week meeting, AbbVie presented late-breaking data analyses that showed both doses of Skyrizi met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo in two Phase III studies. The Lancet published results from pivotal global Phase III clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating Rinvoq (upadacitinib) in adults and adolescents with mild to severe atopic dermatitis who were candidates for systemic treatment.